ACER News and Press, Acer Therapeutics Inc. From 08/15/22

Acer Therapeutics press release ( NASDAQ: ACER ): Q2 GAAP EPS of -$0.17 beats by $0.42 . Cash and cash equivalents were $14.5 million For further details see: Acer Therapeutics GAAP EPS of -$0.17 beats by $0.42

NEWTON, Mass., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious, rare and life-threatening diseases with significant unmet medical needs, today reported fi...

The European Commission granted orphan medicinal product designation to Acer Therapeutics ( NASDAQ: ACER ) and Relief Therapeutics' ( OTCQB:RLFTF ) ( OTCQB:RLFTY ) ACER-001 (sodium phenylbutyrate) to treat patients with Maple Syrup Urine Disease (MSUD). AC...

GENEVA, Switzerland and NEWTON, Mass., Aug. 12, 2022 (GLOBE NEWSWIRE) -- RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief), and its collaboration partner, Acer Therapeutics Inc. (Nasdaq: ACER) (Acer), today announced that the European Commission has granted orphan medi...

Acer Therapeutics ( NASDAQ: ACER ) and partner Relief Therapeutics ( OTCQB:RLFTF ) ( OTCQB:RLFTY ) on Thursday said the U.S. Food and Drug Administration (FDA) had accepted the companies' resubmission of their new drug application for their ACER-001 treatment for p...

NEWTON, Mass. and GENEVA, Switzerland, July 28, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER) (Acer) and its collaboration partner, RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief), today announced the submission of an Investigational New Drug (IND) a...

NEWTON, Mass. and GENEVA, July 28, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER) (Acer) and its collaboration partner, RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief), today announced the U.S. Food and Drug Administration (FDA) has accepted for revie...

Newton, Massachusetts-based Acer Therapeutics ( NASDAQ: ACER ) announced on Monday that the company resubmitted its New Drug Application (NDA) seeking FDA approval of ACER-001 oral suspension for the treatment of patients with urea cycle disorders (UCDs). Also known as sod...

NEWTON, Mass., July 18, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today announced th...

Gainers: MyMD Pharmaceuticals ( MYMD ) +23% . Clovis Oncology ( CLVS ) +22% . iRhythm Technologies ( IRTC ) +22% . Acer Therapeutics ( ACER ) +15% . Atreca ( BCEL ) +12% . Losers: RAPT Therapeutics ( RAPT ) -9% ...